Page 1

Revenio Group Corporation : Interim report January 1 - March 31 , 2021 The figures in parentheses refer to the corresponding period in the previous year unless otherwise stated . Exceptionally high organic growth driven by the company's main products January - March 2021 • • • Net sales totaled EUR 16.8 ( 11.9 ) million , showing an increase of 40.8 % The currency - adjusted growth of net sales in January - March was 44.5 % , or 3.7 percentages stronger than the reported growth The strong development of business was attributable to good sales performance in all of Revenio's key markets . The development of the sales of imaging devices was also positive in the first quarter and there is a willingness to also invest in capital equipment Operating profit was EUR 4.6 ( 2.4 ) million , representing 27.5 % of net sales and growth of 90.4 % . Operating profit adjusted with non - recurring acquisition costs of EUR 0.6 million was EUR 5.2 million , representing 31.3 % of net sales , an increase of 116.6 % EBITDA was EUR 5.3 ( 3.1 ) million , up 72.2 % . EBITDA adjusted with non - recurring acquisition costs of EUR 0.6 million was EUR 5.9 million , representing 35.3 % of net sales , an increase of 92.9 % In March , Revenio announced the acquisition of Oculo . The execution of the transaction is expected to take place in the beginning of the second quarter of 2021. Oculo is an Australian eye care software platform that combines clinical communication , telehealth , remote patient monitoring , and data analytics capabilities Cash flow from operations totaled EUR 0.6 ( -0.3 ) million At its Capital Markets Day held in March , Revenio presented its updated strategy that focuses on clinical eye care solutions Undiluted earnings per share came to EUR 0.141 ( 0.075 ) • The Annual General Meeting was held on March 17 , 2021 Key consolidated figures , EUR million 1-3 / 2021 Net sales Gross margin 16.8 1-3 / 2020 11.9 Change , % 1-12 / 2020 40.8 61.1 12.0 8.5 40.7 43.3 Gross margin , % 71.7 71.7 -0.1 71.0 EBITDA 5.3 3.1 72.2 21.7 EBITDA , % 31.5 25.8 5.7 35.5 Operating profit , EBIT 4.6 2.4 90.4 17.1 Operating profit % , EBIT 27.5 20.4 7.2 28.1 Return on investment , % ( ROI ) 5.2 2.6 2.6 18.1 Return on equity , % ( ROE ) 5.6 3.0 2.6 19.9